The present study demonstrates the efficacy of a candidate cancer vaccine based on IFN-DC loaded with breast tumor organoids and points toward the potential of oxidized cell lysate to enhance tumor immunogenicity. The gene discussed is IFNA1; the disease is neoplasm.